Interactive Report Tool

Increase your understanding of how the Oncotype DX GPS assay refines patient risk levels for more informed treatment decisions.Select an NCCN risk group in step 1 and then add a GPS score in step 2 to see how the combination gives you a more informed risk across multiple clinical endpoints and individualized risk factors.

STEP 1: SELECT AN NCCN RISK GROUP ?

STEP 2: SELECT A GPS RESULT ? The Average GPS score for the NCCN Low risk group is 12

Show adjustable scale from 0 to 100, intervals of 5.

GPS + NCCN®: Very Low Risk


The combination of NCCN® and GPS has resulted in a Downgraded Risk

GPS Score Animation
Text and 3 balloons here
Clinical Interpretation - Clinical Endpoints - Individualized Risk
The combination of GPS and clinical features predicts that this patient's risk is consistent with NCCN Very Low Risk disease. In a clinical validation study including patients with NCCN Very Low, Low, and intermediate Risk, no patient with a GPS result <20 had="" metastasis="" or="" died="" from="" prostate="" cancer="" within="" 10="" years.="">
Making cancer care smarter.®
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.